Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"Co-mutations"”.
-
The Genomic Landscape and Prognostic Impact of KRAS, STK11, and SMARCA4 Mutations and Co-Mutations on Survival Outcomes in Non-Small Cell Lung Cancer
Non-small lung cancer (NSCLC) accounts for 85% of lung cancer cases, and Kirsten rat sarcoma viral oncogene homolog (KRAS), Serine/Threonine Kinase 11 (STK11), and SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4) mutations and co-mutations …
-
Investigation of haematopoietic cell growth and the impact of common mutations in myeloid malignancies
… their function has not yet been characterised as co-mutations in erythroid and myeloid human cell lines. In this light using the CRISPR/Cas9 system, we engineered erythroid and myeloid models of myeloid malignancy in HUDEP2 and KBM5 cells respectively, with homozygous TET2 or heterozygous ASXL1 …
-
An investigation of the role of mutations in the spliceosome machinery in the myelodysplastic syndromes
The myelodysplastic syndromes (MDS) are common myeloid malignancies. Mutations in splicing factor genes (including SF3B1, SRSF2 and U2AF1) occur in over half of MDS patients and result in aberrant pre-mRNA splicing of many target genes, indicating that aberrant spliceosome function plays a key role …
-
MET Alterations in Glioblastoma: Characterization of Patient-Derived Xenografts and Therapeutic Strategies
Glioblastoma is the most commonly diagnosed central nervous system primary malignancy and it is considered a terminal diagnosis with few treatment options available. Glioblastoma tumors frequently develop treatment resistance due in part to their highly heterogenic nature. The heterogeneity of …
-
Genomic Characterization of Response and Resistance to Immunotherapy in Black Patients with Non-Small Cell Lung Cancer
… there remains an urgent clinical need to recognize which patients are expected to benefit from or display primary resistance to this type of therapy. Given the high morbidity and mortality of Black patients in this setting, predicting which individuals are most likely to derive a durable …
-
A NOVEL PHF6-PHIP CHROMATIN COMPLEX REPRESSES LEUKEMIA STEMNESS
… myeloid leukemia (AML) is characterized by uncontrolled proliferation of myeloid progenitors accompanied by a differentiation arrest. This aggressive bone marrow malignancy is a heterogeneous disease with the types of mutations and co-mutations playing a major role in determining the disease …
-
New therapeutic concepts for BRAF-driven colorectal cancer
… BRAFV600E mutation occurs in about 10 % of colorectal cancer (CRC) patients and confers a poor prognosis. In order to evaluate novel treatment approaches such as the combination of immunotherapy with kinase inhibition, syngeneic preclinical models are urgently needed, but remain scarce. In …
-
The identification of novel therapy options in difficult to treat non-small cell Lung cancer
… for treatment. This thesis focuses on three common subsets of smoking related lung cancer: STK11-mutant lung adenocarcinoma, KRAS-mutant lung adenocarcinoma and 3q amplified squamous cell lung cancer. In STK11-mutant lung cancer, this thesis seeks to explore resistance to mTORC1/2 inhibition. …
-
Impact of IDH1 and IDH2 Mutation Detection at Diagnosis and in Remission in Acute Myeloid Leukemia Patients Receiving Allogeneic Transplantation
… 1 or 2 gene (IDH1 and IDH2). Therefore, these mutations are among the common ones in AML. However, the prognostic significance of mutated IDH in AML patients remains controversial. Several research groups reported distinct outcomes within specific patient subsets depending on the biological and …